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Abstract
Obesity and obesity co-morbidities are associated with a low grade inflammation and elevated serum levels of acute phase
proteins, including serum amyloid A (SAA). In the non-acute phase in humans, adipocytes are major producers of SAA but
the function of adipocyte-derived SAA is unknown. To clarify the role of adipocyte-derived SAA, a transgenic mouse model
expressing human SAA1 (hSAA) in adipocytes was established. hSAA expression was analysed using real-time PCR analysis.
Male animals were challenged with a high fat (HF) diet. Plasma samples were subjected to fast protein liquid
chromatography (FPLC) separation. hSAA, cholesterol and triglyceride content were measured in plasma and in FPLC
fractions. Real-time PCR analysis confirmed an adipose tissue-specific hSAA gene expression. Moreover, the hSAA gene
expression was not influenced by HF diet. However, hSAA plasma levels in HF fed animals (37.764.0 mg/mL, n=7) were
increased compared to those in normal chow fed animals (4.860.5 mg/mL, n=10; p,0.001), and plasma levels in the two
groups were in the same ranges as in obese and lean human subjects, respectively. In FPLC separated plasma samples, the
concentration of hSAA peaked in high-density lipoprotein (HDL) containing fractions. In addition, cholesterol distribution
over the different lipoprotein subfractions as assessed by FPLC analysis was similar within the two experimental groups. The
established transgenic mouse model demonstrates that adipose tissue produced hSAA enters the circulation, resulting in
elevated plasma levels of hSAA. This new model will enable further studies of metabolic effects of adipose tissue-derived
SAA.
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Introduction
Obesity, and especially central obesity, is a major risk factor
for cardiovascular disease [1]. The adipose tissue produces a
variety of adipokines that act both locally within the adipose tissue
and systemically when released into the circulation. Obesity is
associated with a low grade inflammation with slightly elevated
serum levels of acute phase proteins including C-reactive protein
(CRP) and serum amyloid A (SAA) [2,3]. Elevated serum levels of
SAA are associated with insulin resistance, type 2 diabetes and
may have a prognostic value for cardiovascular disease [4,5,6,7,8].
In the acute phase response, SAA is produced by the liver and
its serum levels can rise thousand-fold, but the function of SAA is
poorly understood. Extrahepatic production of SAA has been
found [9], and we, and others, have previously reported that in the
non acute phase, adipocytes are the main producers of SAA in
obese subjects [10,11]. SAA gene expression is increased in human
hypertrophic adipocytes [12], cells that are known to be associated
with obesity and insulin resistance [13]. In addition, SAA serum
levels are correlated with measures of obesity and reduced during
diet-induced weight loss [10]. Furthermore, SAA release from
human adipose tissue in vitro has been shown to correlate with SAA
gene expression [2]. Thus, it is likely that, in humans, the in-
creased fat mass in obesity contributes substantially to SAA levels
in the circulation.
Previous studies in humans have shown that SAA may have
various effects including promoting proinflammatory cytokine
production [2], inducing lipolysis [2,14], and increasing chemo-
taxis of inflammatory cells [15,16]. Furthermore, SAA can remove
excess cholesterol from sites of inflammation (reviewed in [17]),
and has been suggested to play a role in cholesterol efflux within
the adipose tissue [18]. SAA can act as an apolipoprotein, and
the majority of SAA in the blood is associated with high-density
lipoprotein (HDL). SAA causes displacement of ApoA-I, the
predominant HDL apolipoprotein, in vitro [19], which may alter
HDL properties in a proatherogenic way. Proteoglycans are com-
ponents of the extracellular matrix and may be important for
deleterious lipoprotein retention. SAA contains proteoglycan
binding domains [20] and has been suggested to mediate pro-
atherosclerotic lipid and lipoprotein retention in the vessel wall. In
vitro, a higher amount of SAA on the HDL particles increases the
binding of HDL to proteoglycans [21] and the idea is further
supported by co-localization of SAA with ApoA-I in atheroscle-
rotic lesions in mice [21,22]. Interestingly, a recent publication
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vascular proteoglycan synthesis in a pro-atherogenic manner [23],
suggesting that SAA could be a direct link between low-grade
inflammation in adipose tissue and cardiovascular disease in obese
subjects.
The SAA protein is transcribed from the two homologous genes
SAA1/SAA2 in humans, and from Saa1/Saa2 in mice. However,
there are also species differences in the SAA gene family. In mice,
Saa3 is extrahepatically expressed, while SAA3 in humans is a
pseudo gene. Hence, in mice, the Saa1/Saa2 and Saa3 genes are
expressed in adipose tissue whereas in humans only the SAA1/
SAA2 genes are transcribed. It has also been shown that, only the
expression of Saa3 is increased after HF diet in mice [24]. Even
though obese mice also display increased SAA levels in serum,
absence of SAA3 in the serum was recently reported [25],
indicating that in obese mice, SAA in the circulation has a hepatic
origin.
The mature protein encoded by SAA1/SAA2 is highly
conserved between mouse and human [26]. In contrast, the
mouse SAA1/SAA2 and SAA3 proteins are distinct proteins with
a sequence homology of only 63–65% [26]. Because of these
species differences over expression of human SAA1 is likely to be
the most suitable model when addressing questions related to
adipose tissue expression of SAA in human obesity. Others have
studied the effects of the human SAA protein (hSAA) in mice using
adenoviral over expression [23,27,28,29]. However, this method
only results in a short-term hSAA production from the liver. Thus,
these studies have not mimicked the chronic increase in adipose
tissue-derived SAA in obese humans. We have therefore developed
a mouse model where hSAA is over expressed in adipose tissue to
mimic the situation in human obesity. Consequently, this model
enables studies of the systemic and local effects of adipocyte-
derived SAA and provides a tool that can be used to define the role
of adipose tissue derived SAA in the development of metabolic
disease.
Methods
Ethics statement
All manipulations involving mice were performed using
protocols approved by the local Ethics Committee for Animal
Studies at the Administrative Court of Appeals in Gothenburg,
Sweden, approval numbers 201-2006 and 281-2008.
Animals
Transgenic founder mice were generated on a C57BL/6J
background. The cDNA from human SAA1 (hSAA) was cloned
into the pCR 2.1 vector (Invitrogen, Carlsbad, CA) and verified
by sequencing. A SmaI-EcoRV digested fragment containing
hSAA1 was ligated into Sma1 linearized pBluescript SK II+ vector
(Stratagene, La Jolla, CA) downstream of the fatty acid binding
protein 4 (aP2) promoter (kindly provided by Dr. Bruce Spie-
gelman) [30]. A SmaI-BamHI fragment containing the SV40
polyadenylation sequence from the pSI vector (Promega, Madison,
WI) was ligated into BamHI-SmaI linearized pBS SK+ vector. A
Sma1-HincII fragment containing aP2-hSAA1 was inserted into
EcoRV linearized pBluescript SK+ (Stratagene, La Jolla, CA)
upstream of the SV40 polyadenylation sequence. Finally, a
BamHI-BglII blunted rabbit b-globin gene intron was inserted
into the SmaI site, downstream of aP2-hSAA and upstream of the
polyadenylation site. A 7190 bp SacII-XhoI fragment (Figure 1)
was microinjected into C57BL/6J fertilized eggs using pronuclei
injection and eggs were implanted in the oviduct of pseudopreg-
nant recipients. All restriction enzymes were purchased from New
England Biolabs (Ipswich, MA). Transgenic mice were identified
by PCR with forward and reverse primers 59-CCAGGGAGAAC-
CAAAGTTGA and 59-CCCGAGCATGGAAGTATTTG, re-
spectively. The endogenous b-globin gene was co-amplified as an
internal control.
Subsequent breeding was done against C57BL/6J mice
(Charles River, Sulzfeld, Germany) to generate heterozygous
SAA-transgenic mice. Male animals of F2 or later generations
were used in experiments. Animals were weaned at 3 weeks of age
and housed 3–6 per cage in a temperature-controlled (25uC)
facility with a 12-h light-dark cycle with free access to chow and
water. From the age of 13 weeks age-matched wild type and hSAA
transgenic animals were fed either a normal chow (NC) or a
pelleted high fat (HF) diet (60 kcal% fat; D12492, Research Diets,
New Brunswick, NJ). At the end of the experiment mice were
sacrificed after a 4-hour fast. Using heart puncture blood was
collected in potassium EDTA tubes (Sarstedt, Nu ¨mbrecht,
Germany) from Isofluran (Baxter, Kista, Sweden) inhalation
anesthetised animals. Brown adipose tissue (BAT), epididymal
adipose tissue (eWAT), retroperitoneal adipose tissue (rWAT),
gastrocnemius muscle, heart, liver, kidneys and spleen, were
dissected, weighed, snap frozen in liquid nitrogen and stored at
280uC until RNA extraction.
Body composition
Total body weight was recorded at 11 weeks of age and weekly
during the HF or corresponding NC feeding period. Analysis of
total body fat was performed by dual energy X-ray absorptiometry
(DEXA) using the Lunar PIXImus II Densitometer with version
2.10.041 software (GE Healthcare, Waukesha, WI) after 17 weeks
of HF or NC diet. During DEXA analysis, mice were anesthetized
with Isofluran.
RNA preparation and gene expression analysis
RNA from the dissected tissues was prepared using the RNeasy
lipid mini kit with TissueLyser homogenization (Qiagen, Chats-
worth, CA) and the RNA was then reverse transcribed using
the High Capacity cDNA RT kit (Applied Biosystems, Foster
City, CA). Real-time PCR analysis was performed using TaqMan
Gene Expression Master Mix and cDNA corresponding to 10
ng of RNA per reaction with an ABI Prism 7900HT (Applied
Biosystems). The following TaqMan gene expression assays
were used; Hs00761940_s1 (human SAA), Mm00441203_m1
(mouse Saa3), and Mm00445878_m1 (mouse Fabp4). The
Mm00725448_s1 assay was used for detection of the endoge-
nous reference transcript ribosomal protein, large, P0 (Rplp0; all
reagents were from Applied Biosystems). A standard curve was
Figure 1. Generation of transgenic mice overexpressing hSAA
in adipose tissue. A schematic representation of the aP2 promoter-
hSAA fusion gene. Human SAA1 cDNA was ligated to the aP2 promoter/
enhancer as described in ‘‘Methods’’. Dotted box aP2 promoter, hatched
box, rabbit b-globin intron, grey box, polyadenylation signal. Restriction
enzyme digestion with XhoI and SacII enzymes generated fragments of
7.2 kilobases that were used in pronuclei injections. Locations of
genotyping primers are indicated with arrows.
doi:10.1371/journal.pone.0019609.g001
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from pooled RNA. Samples and standards were analysed in
triplicate.
Blood measurements
After 16 weeks of HF or NC diet, a 4-hour fast preceded
blood sampling from the tail vein. Basal glucose and insulin were
measured using Accu-Check glucometer (Roche, Stockholm,
Sweden) and Ultrasensitive mouse insulin enzyme-linked immu-
nosorbent assay (ELISA) Kit (Chrystal Chem Inc., Downers
Grove, IL), respectively. Plasma pools (n=7–10 animals), from
blood collected by heart puncture, were subjected to fast protein
liquid chromatography (FPLC) gel filtration on a Superose 6
(10/300GL) column (GE Pharmacia AKTA explorer) [31]. HDL
from hSAA-transgenic and wild type mice (n=6 in each group)
was isolated by ultracentrifugation as previously described [32].
Triglycerides and cholesterol were measured in FPLC fractions
and in whole plasma using Infinity Cholesterol and Infinity
Triglycerides (Triolab AB, Gothenburg, Sweden) with Multi-
constituent Calibrator 1E65-04 (Abbott, Solna, Sweden) used as
reference. The hSAA protein was measured in plasma from hSAA
transgenic mice, in pools of two adjacent FPLC fractions, and
in ultracentrifugation samples using a Human SAA ELISA Kit
(Biosource, Camarillo, CA). Mouse SAA protein (mSAA) was
measured in plasma using the Mouse SAA ELISA Kit (Tridelta
Development Ltd., Co. Kildare, Ireland).
Statistical Analysis
Data is reported as mean 6 standard deviation (SD) unless
indicated otherwise. Statistical analysis was performed using SPSS
(version 16.0; SPSS; Chicago, IL, USA). Differences between
groups were assessed with the Mann-Whitney U-test. Differences
in growth curves were assessed with repeated measures analysis of
variance (ANOVA). Nonparametric correlations were performed
using Spearman rank correlation test. A p-value less than 0.05 was
regarded statistically significant.
Results
Analysis of mRNA expression in mice overexpressing
hSAA in adipose tissue
A construct containing the mouse aP2 promoter/enhancer
region was used to generate a mouse model with adipose tissue
specific expression of hSAA (Figure 1). Three transgenic founders
were obtained from pronuclei injections and one transgenic strain
was established. Transgenic animals were viable, produced normal
litter sizes and had no visible phenotype. Real-time PCR analysis
confirmed that the transgenic construct was specifically expressed
in adipose tissue (Figure 2A), and that the hSAA transcript was
undetectable in wild type animals fed NC or HF diet (n=4,
respectively; data not shown). In muscle and heart, the hSAA
expression levels were just above the lower limit of detection and,
as expected, hSAA expression was undetectable in tissues from
wild type animals. There was no effect of HF feeding on hSAA
gene expression in eWAT or in rWAT compared with samples
from NC fed animals (Figure 2A). There was no difference in
Fabp4 (aP2) expression in transgenic compared to wild type mice
(Figure 2B) in eWAT, but the expression was significantly lower in
HF compared to NC fed hSAA animals (Figure 2B; p=0.011). In
HF fed animals the expression of Saa3 in eWAT was reduced in
hSAA compared with wild type animals (Figure 2C, p=0.028).
However, in animals fed NC the Saa3 expression in adipose tissue
was unchanged.
Analysis of growth and body composition in hSAA
transgenic animals
At 11 weeks of age, the body weights of hSAA male mice
(25.062.1 g, n=18) were slightly lower compared to wild type
male mice (26.362.0 g, n=19; p=0.046). Groups of animals
were challenged with a HF diet resembling a western diet. Even
though there was an initial difference in body weight between
hSAA and wild type animals, there was no difference in weight
gain between hSAA and wild type mice fed NC or when chal-
lenged with HF diet (Figure 2D).
Total body fat content was measured with DEXA after 17
weeks of either NC or HF diet. Total body fat was similar in hSAA
and wild type male mice on the same diet (data not shown). In line
with this finding, there were no major discrepancies in adipose
tissue depot sizes (Table 1). At the end of the study, hSAA animals
fed a NC diet had similar adipose tissue depot sizes as wild type
animals both in absolute values and when related to body weight
(Table 1). Transgenic hSAA HF fed animals displayed significantly
increased eWAT depot size both in absolute mass (p=0.019) and
when expressed as percentage of body weight (p=0.034)
compared to wild type mice fed a HF diet. The same animals
displayed no change in rWAT or BAT mass.
Transgenic hSAA animals fed HF diet had reduced absolute
weight of kidneys and heart (p=0.023 and p=0.049, respectively).
However, when relating to body weight, these significances
were lost. The weight of kidneys and heart from animals fed
normal chow was similar between wild type and hSAA animals.
Furthermore, hSAA animals on HF, but not on NC, had sig-
nificantly reduced spleen weight compared to wild type mice both
in absolute mass and in proportion to body weight (p=0.001 for
both tests). The weights of gastrocnemius muscle, liver or brain
were similar in wild type and hSAA animals fed NC or a HF diet
(data not shown).
Analysis of plasma levels of SAA and markers of
metabolic status
An ELISA specific for human SAA was used to analyse hSAA
concentrations in plasma from hSAA transgenic animals. We
found that the hSAA protein was present in plasma from both NC
(n=7) and HF (n=10) fed hSAA animals, while hSAA was
undetectable in plasma from wild type animals (n=8). Further-
more, significantly increased levels of hSAA were found in plasma
from HF fed compared to NC fed hSAA animals (p=0.0001,
Figure 3A). The plasma concentrations of mouse SAA were
measured with an ELISA that showed no cross reactivity towards
the hSAA protein (data not shown). The concentration of mSAA
in three plasma samples (from one hSAA and two wild type mice)
from HF fed animals were above detection limit of the assay.
These samples were omitted from mSAA analyses. Plasma levels
of mSAA were increased in HF compared to NC fed animals
(p,0.0001; Figure 3B). We found no difference in plasma
mSAA levels between hSAA and wild type mice (Figure 3B).
Total amounts of plasma cholesterol and triglycerides were also
measured in individual plasma samples but the levels were
unaltered between hSAA and wild type animals within both the
NC fed group (cholesterol: 3.060.2 and 3.060.4 mmol/L;
triglycerides: 0.760.08 and 0.760.09 mmol/L in wild types and
hSAA mice, respectively) and the HF fed group (cholesterol:
5.560.9 and 5.361.0 mmol/L; triglycerides: 0.5260.13 and
0.5560.09 mmol/L in wild types and hSAA mice, respectively).
Blood glucose and insulin were measured after a 4-hour fast in
animals fed 16 weeks HF diet, but neither glucose nor insulin levels
differed between wild type and hSAA animals (glucose: 12.962.3
SAA Overexpression in Adipose Tissue
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wild types and hSAA mice, respectively).
Plasma levels of SAA in relation to body composition and
markers of metabolic status
In humans, SAA plasma levels are correlated with the amount
of body fat [10]. Therefore, we wanted to test if the amount of
adipose tissue was associated with plasma hSAA levels in hSAA
animals. Figure 3C shows that hSAA plasma levels in hSAA
animals fed NC and HF diet correlate with the total amount of
body fat measured by DEXA analysis (r=0.88, p=4*10
26). When
the results were analysed separately for animals given NC and HF
diets, the correlation remained significant (r=0.65, p=0.043) in
animals challenged with HF diet only. Plasma mSAA levels
correlated with body weight (r=0.79 p=1.8*10
27), and total
amount of body fat (r=0.71 p=1.0*10
25; Figure 3D).
The relationships between plasma hSAA and total amount of
cholesterol, total amount of triglycerides, body weight, and
adipose tissue hSAA expression were also analysed. Plasma levels
of hSAA correlated with body weight and plasma levels of total
Figure 2. Analyses in hSAA transgenic male mice: gene expression, and animal growth. (A) hSAA gene expression in various tissues
including epididymal white adipose tissue (eWAT), retroperitoneal white adipose tissue (rWAT) and brown adipose tissue (BAT) was measured in
hSAA transgenic animals (n=7) fed NC diet. hSAA gene expression was also measured in eWAT and rWAT from hSAA mice (n=10) after 18 weeks of
HF diet. Expression was normalized to Rplp0. (B) and (C) Gene expression of Fabp4 and Saa3 in eWAT (n=7–10 male animals in each group),
respectively. Expression was normalized to Rplp0. (D) Growth curves of wild type and hSAA transgenic animals fed NC (dashed line) or HF (solid line)
diet for 18 weeks. Open circles, wild type mice; filled squares hSAA mice (n=7–10 per group).*, p,0.05. Values are given as mean 6 SEM.
doi:10.1371/journal.pone.0019609.g002
Table 1. Body weight and adipose tissue depots.
NC
Absolute weight
(mg)
Relative weight
(% of body weight) HF
Absolute weight
(mg)
Relative weight
(% of body weight)
Body wt (g) hSAA 40.064.3 - hSAA 49.864.3 -
Wt 41.263.1 - Wt 52.563.8 -
BAT hSAA 100619 0.2560.04 hSAA 133644 0.2660.08
Wt 117623 0.2860.05 Wt 151629 0.2960.05
eWAT hSAA 18376298 4.5960.48 hSAA 18736438* 3.8461.18*
Wt 18596266 4.5160.47 Wt 15096183 2.8960.43
rWAT hSAA 544664 1.3760.19 hSAA 7176113 1.4560.27
Wt 547655 1.3360.16 Wt 6886139 1.3160.24
Values are presented as mean6SD. Body wt, body weight; NC, normal chow; HF, high fat; BAT, brown adipose tissue depot; eWAT, epididymal white adipose tissue
depots; rWAT, retroperitoneal white adipose tissue depots; hSAA, hSAA male animals; Wt, wild type male animals. n(NC, hSAA)=7, n(NC, Wt)=8, n(HF, hSAA)=10 and
n(HF, Wt)=10.
*p,0.05 between hSAA and Wt animals.
doi:10.1371/journal.pone.0019609.t001
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(Table 2). However, both correlations were lost when analysing
HF and NC fed animals separately (Table 2). Neither hSAA gene
expression in eWAT nor in rWAT correlated to plasma hSAA
levels (Table 2). The hSAA gene expression in BAT was analysed
in NC fed animals only and correlated with plasma hSAA levels
(Table 2).
Lipoprotein profiles and distribution of hSAA in plasma
from transgenic mice
To investigate whether adipose tissue derived hSAA can modify
the composition of lipoproteins, pooled plasma samples (n=7–10)
were subjected to FPLC gel filtration. In response to the 18 week
long HF diet, lipoprotein cholesterol content in FPLC fractions
increased in a similar way in both wild type and hSAA animals
compared to NC fed animals (Figure 4A). Triglyceride distribution
among lipoproteins was not changed (data not shown) between
wild type and hSAA animals fed NC or a HF diet, respectively.
The hSAA concentration, analysed with ELISA in pooled adjacent
FPLC-fractions, peaked in HDL containing fractions (Figure 4B)
and no hSAA was detected in other fractions. This was also
supported by the presence of hSAA in HDL fractions isolated by
ultracentrifugation of six individual samples from NC fed hSAA
animals (data not shown). Furthermore, hSAA levels in HDL
containing FPLC fractions from HF challenged animals were
increased compared to the same fractions from animals fed NC
diet (Figure 4B).
Discussion
We here report the establishment and initial characterization of
a mouse model with transgenic expression of human acute phase
SAA in adipocytes under the control of the aP2 enhancer/
promoter. In hSAA transgenic animals, the hSAA protein was
present in plasma, demonstrating that adipose tissue-derived SAA
is released into the circulation in this model. Furthermore, plasma
levels of hSAA in the transgenic mice were similar to those
observed in humans and the levels were associated with the
Figure 3. Analyses of SAA plasma levels. (A) Plasma levels of hSAA in NC (n=7) compared to HF (n=10) fed male animals. (B) Plasma levels of
mSAA in NC (wild type (Wt) and hSAA; n=7 and n=6, respectively) and HF fed (Wt and hSAA; n=8 and n=9, respectively) animals. (C) Plasma levels
of hSAA in relation to body fat quantified using DEXA analysis in transgenic male animals. (D) Plasma levels of mSAA in relation to body fat quantified
using DEXA analysis in wild type (n=15) and hSAA (n=15) transgenic male animals.***, p,0.001. Values are given as mean 6 SEM.
doi:10.1371/journal.pone.0019609.g003
Table 2. Spearman correlation coefficients (r) between hSAA
plasma levels, body weight, and plasma lipids in hSAA male
animals.
r(NC+HF) p r(NC) p r(HF) p
Body weight (g) 0.79 0.00043 0.64 n.s. 0.19 n.s.
Plasma cholesterol
(mmol/L)
0.77 0.0003 0.50 n.s. 0.08 n.s.
Plasma triglycerides
(mmol/L)
20.35 n.s. 0.64 n.s. 0.06 n.s.
eWAT hSAA expression 0.24 n.s. 0 n.s. 0.44 n.s.
rWAT hSAA expression 20.3 n.s. 0.82 n.s. -0.16 n.s.
BAT - - 0.79 0.036 - -
Values are presented as mean6SD. n(NC+HF)=17, n(NC)=7, n(HF)=10, eWAT,
epididymal white adipose tissue; rWAT, retroperitoneal white adipose tissue;
BAT, brown adipose tissue.
*** p,0.001, * p,0.05, n.s. not significant.
doi:10.1371/journal.pone.0019609.t002
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body fat and serum SAA levels in human subjects. We found no
indication of an increased expression of mouse SAA genes in the
hSAA transgenic mice. On the contrary hSAA mice subjected to
HF diet displayed reduced expression of the mouse Saa3 gene in
adipose tissue. Furthermore, plasma levels of mSAA were similar
in hSAA and wild type mice and the levels were highly correlated
with body fat content as is the case in man [10]. Analyses using
both FPLC and ultracentrifugation demonstrated that the hSAA
concentration peaked in HDL containing plasma fractions. Hence,
this mouse model mirrors the SAA phenotype seen in human
obesity and therefore provides a suitable model to determine the
direct effects of adipose tissue-derived SAA on the cardiovascular
system.
The hSAA transgenic mice displayed no visible phenotype.
Although the hSAA mice had slightly lower body weight
compared to wild type mice at 11 weeks of age, growth during
the 18 subsequent weeks on NC or HF diet did not differ between
transgenic and wild type animals. Therefore, we can not rule
out that the initially observed difference in weight between wild
type and hSAA mice was a spurious finding. hSAA mice
challenged with HF diet had reduced spleen sizes, which may
indicate an effect on the immune system. Total body fat mass was
similar between hSAA and wild type mice, but the epididymal
depot mass was decreased after HF diet in wild type animals
compared to NC fed mice, and compared to hSAA transgenic
mice. This decrease resulted in a significant difference between
wild type and transgenic mice. However, if these findings are
related to the hSAA over-expression requires further analysis.
The aP2 promoter/enhancer has previously been used in se-
veral projects to induce adipocyte specific over-expression [30]. In
our study, real-time PCR analysis of hSAA gene expression in
various tissues confirmed that hSAA was predominantly expressed
in adipose tissue (Figure 2A). In the analysed tissue panel, only
very low levels of hSAA expression were detected in muscle and
heart. Gene expression of hSAA in three adipose tissue depots
revealed different levels of expression: BAT.rWAT.eWAT. This
expression pattern has previously been reported in transgenic mice
where the aP2 promoter/enhancer was used [33,34]. It may be
speculated that due to the small size of the BAT compared to
WAT depots it is possible that the majority of hSAA is produced in
WAT in the hSAA transgenic mice. However, this remains to be
shown.
Previous studies have shown that SAA serum levels are elevated
in obese human subjects and reduced in response to weight loss
[2,10,35]. Furthermore, we have shown that serum levels of SAA
are correlated with the amount of adipose tissue [10]. In mice, it
was recently shown that SAA3, the SAA isoform expressed in
adipose tissue, does not enter the circulation [25] and that this
could be due to SAA3 hyaluron interaction within adipose tissue
[36]. In obese human subjects, both the increased SAA expression
in adipose tissue and the increase in adipose tissue mass contribute
to elevated levels of SAA in serum [2,10]. In the present study, we
have created a model where adipose tissue-derived hSAA does
Figure 4. Distribution of cholesterol and hSAA in lipoproteins. Pooled plasma samples from transgenic (hSAA) and wild type (Wt) male
animals fed either NC or HF diet (n=7–10 per group) were subjected to FPLC as detailed in ‘‘Methods’’. (A) Cholesterol levels in plasma FPLC fractions
from Wt and hSAA animals. (B) hSAA levels in plasma FPLC fractions from hSAA animals.
doi:10.1371/journal.pone.0019609.g004
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were increased compared to the levels in the leaner NC fed hSAA
mice but the expression levels of hSAA in adipose tissue were
unchanged suggesting that the high hSAA levels in plasma are due
to the increased adipose tissue mass. This is further supported by
the high correlation between plasma levels of hSAA and amount of
body fat. In line with previous studies with long-term HF feeding
[37,38,39] we found a decreased gene activity of the aP2/Fabp4
gene in epididymal adipose tissue from HF fed mice. A reduced
induction of the aP2 promoter may explain why the level of hSAA
expression was not increased in HF animals.
Importantly, in the established model, plasma hSAA levels in
transgenic mice fed HF and NC were in the same ranges as in
obese and lean human subjects [2,10], supporting the idea that this
model is suitable for studies aimed at elucidating the effects of
adipose tissue derived SAA. Furthermore, this model can be used
to clarify the mechanisms for SAA release from adipocytes and
macrophages, where the aP2 promoter/enhancer is active [40].
SAA may affect the development of cardiovascular disease
through many different mechanisms. For instance, SAA is
involved in cholesterol transport, including cholesterol efflux
(reviewed in [17]), and a recent report demonstrated that SAA
reduces reverse cholesterol transport in vivo [41]. In the circulation,
SAA is predominantly associated with HDL [42], and SAA-HDL
displays potentially reduced antioxidant properties [43] as well as
SAA-mediated lipoprotein retention [22]. In the present study,
plasma analyses in transgenic mice suggested that hSAA was
associated with HDL, indicating that adipose tissue-derived hSAA
has similar properties as circulating SAA in man. Furthermore, the
presence of hSAA in plasma did not affect the size- or cholesterol-
content of the lipoproteins. This is consistent with unaltered
lipoprotein profiles in mice with short-term adenoviral overex-
pression of hSAA [23,27], and with a recent report of unaltered
HDL cholesterol levels in a SAA1 and SAA2 double knock-out
mouse model [44]. Wilson et al. demonstrated that SAA promotes
vascular proteoglycan synthesis in vitro and most importantly, that
a short-term adenoviral-induced hSAA production was sufficient
to obtain pro-atherogenic proteoglycan synthesis in vivo [23].
However, atherosclerosis induced by hSAA was not demonstrated
[23], possibly due to a rapid decline of adenoviral-induced hSAA
plasma levels. In contrast to previous studies of short-term effects
of adenoviral-induced liver-produced hSAA, our model enables
the study of long-term hSAA effects.
Elevated CRP concentration in the blood is a well recognized
risk factor for future cardiovascular disease, although some studies
argue against a causative role for CRP [45,46]. Serum levels of
SAA are correlated with levels of CRP and also with cardiovas-
cular risk factors [6] and SAA levels have a prognostic value, in
some cases working as a better predictor for clinical outcome than
CRP [4,5]. In mice, CRP levels do not respond to inflammatory
stimuli, making mouse models suitable for studying cardiovascular
effects of SAA without interference of CRP effects. Furthermore,
SAA but not CRP, directly promotes vascular proteoglycan
synthesis in a pro-atherogenic manner [23]. In man, SAA serum
levels have been reported to be associated with intima-media
thickness (IMT), both in chronic disease and in young healthy
asymptomatic subjects [47,48]. Furthermore, SAA is co-localized
with apoB in atherosclerotic lesions in HF fed apoE2/2 mice
[49]. In hyperlipidemic mice, SAA was co-localized with apoA-I
[21,22], apoB [22], and SAA plasma levels were correlated with
atherosclerotic lesion area [21]. These data, taken together with
the fact that serum levels of SAA are elevated in human obesity,
suggest that adipose tissue-derived SAA is an important link
between adiposity and the development of cardiovascular disease.
In conclusion, we have established a transgenic mouse model
with adipose tissue-specific expression of hSAA under the control
of the aP2 promoter/enhancer. The increased adipose tissue-
derived hSAA plasma levels in HF fed hSAA mice, correlated with
amount of adipose tissue and, in plasma, hSAA concentration
peaked in HDL containing fractions. Thus, the established model
is similar to the situation found in human obesity and will provide
a novel tool for studies of the direct metabolic and vascular effects
of adipose tissue-derived hSAA.
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